| Drug name |
Drug type |
Disease/phenotype |
Mechanism of action(MoA) |
Phase |
Status |
Source |
| SELINEXOR | Small molecule | acute myeloid leukemia | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | breast cancer | Exportin-1 inhibitor | 2.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | acute myeloid leukemia | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | myelodysplastic syndrome | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | ovarian carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | acute myeloid leukemia | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm of mature B-cells | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | diffuse large B-cell lymphoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | hepatocellular carcinoma | Exportin-1 inhibitor | 1.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | COVID-19 | Exportin-1 inhibitor | 2.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | breast cancer | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | dedifferentiated liposarcoma | Exportin-1 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | squamous cell carcinoma | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | metastatic melanoma | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | acute lymphoblastic leukemia | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | mixed phenotype acute leukemia | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | myelodysplastic syndrome | Exportin-1 inhibitor | 2.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | Thymoma | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | metastatic melanoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm of mature B-cells | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | endometrial cancer | Exportin-1 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | diabetic foot | Exportin-1 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | glioblastoma multiforme | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | alveolar soft part sarcoma | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | rectum cancer | Exportin-1 inhibitor | 1.0 | Unknown status | ClinicalTrials |
| SELINEXOR | Small molecule | acute lymphoblastic leukemia | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | unspecified peripheral T-cell lymphoma | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | urothelial carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | diffuse large B-cell lymphoma | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | acute myeloid leukemia | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | lymphoma | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | colorectal neoplasm | Exportin-1 inhibitor | 1.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | cutaneous melanoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | COVID-19 | Exportin-1 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | AL amyloidosis | Exportin-1 inhibitor | 0.5 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | acute myeloid leukemia | Exportin-1 inhibitor | 2.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | diffuse large B-cell lymphoma | Exportin-1 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | myelodysplastic syndrome | Exportin-1 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | Richter syndrome | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | Fallopian Tube Carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | endometrial cancer | Exportin-1 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | glioblastoma multiforme | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | metastatic colorectal cancer | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | prostate cancer | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | breast carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | diffuse large B-cell lymphoma | Exportin-1 inhibitor | 4.0 | - | DailyMed |
| SELINEXOR | Small molecule | primary peritoneal carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | myelofibrosis | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | gliosarcoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | non-small cell lung carcinoma | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | acute leukemia of ambiguous lineage | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | chronic myelogenous leukemia | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | squamous cell lung carcinoma | Exportin-1 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 2.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | melanoma | Exportin-1 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | Thymoma | Exportin-1 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| SELINEXOR | Small molecule | cancer | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | small cell lung carcinoma | Exportin-1 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SELINEXOR | Small molecule | diffuse large B-cell lymphoma | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | sarcoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm | Exportin-1 inhibitor | 4.0 | - | ATC |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm of mature B-cells | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | myelofibrosis | Exportin-1 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | neoplasm of mature B-cells | Exportin-1 inhibitor | 1.0 | Suspended | ClinicalTrials |
| SELINEXOR | Small molecule | renal cell carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | multiple myeloma | Exportin-1 inhibitor | 4.0 | - | FDA,DailyMed |
| SELINEXOR | Small molecule | lymphoid neoplasm | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |
| SELINEXOR | Small molecule | cancer | Exportin-1 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| SELINEXOR | Small molecule | non-small cell lung carcinoma | Exportin-1 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SELINEXOR | Small molecule | soft tissue sarcoma | Exportin-1 inhibitor | 1.0 | Completed | ClinicalTrials |